AbbVie's blood cancer therapy lowers disease progression, death risk in trial - Reuters
AbbVie's blood cancer therapy lowers disease progression, death risk in trial Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxPYlFCaXhXMFV1NC1mLXZrZUtHdTJMVXlWM0otNHFWTG9tUUpOQkZ0d3Jrck5lRXJEOTk2TlIyUDFoeTVIaWs4ZWNtR0g0SkpHNmI0UUQ1NGdlVVFoQnVrVGdwQUEtSDdQQmZoODBRNWZNcTl3a2R2OFMwNkZiVG1aYm4yRXpUekpQNFZxamZmMkc1TVpTZ0toMDB0cXVYWFp0aHUyeVY1R3VxUnZiUlZzVjdLSTltSXl3YmkxRGZjZVFiaDB4?oc=5" target="_blank">AbbVie's blood cancer therapy lowers disease progression, death risk in trial</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
US FDA approves AbbVie's drug for Parkinson's disease - reuters.com
US FDA approves AbbVie's drug for Parkinson's disease reuters.com
September 25, 2026 at 10:57 PMUS FDA advisers endorse Grail cancer test's benefits in key vote - Reuters
US FDA advisers endorse Grail cancer test's benefits in key vote Reuters
September 23, 2026 at 11:03 PMMerck's drug for diabetes-related eye disease meets trial goal - Reuters
Merck's drug for diabetes-related eye disease meets trial goal Reuters
September 24, 2026 at 02:52 PMRoche's obesity drug boosts blood sugar control, drives 15.5% weight loss in mid-stage trial - Reuters
Roche's obesity drug boosts blood sugar control, drives 15.5% weight loss in mid-stage trial Reuters
September 22, 2026 at 11:25 AMNEWSLETTER: Genetic discovery yields clues toward reversal of Alzheimer's brain damage - Reuters
NEWSLETTER: Genetic discovery yields clues toward reversal of Alzheimer's brain damage Reuters
September 25, 2026 at 11:15 AMNvidia, QIA-backed Iambic Therapeutics files for US IPO as biotech boom rolls on - Reuters
Nvidia, QIA-backed Iambic Therapeutics files for US IPO as biotech boom rolls on Reuters
September 21, 2026 at 10:32 PM